14611-51-9 Category:
  • # LGM Pharma is a Selegiline CAS# 14611-51-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Selegiline
  • CAS #: 14611-51-9
  • Mode of Action:

    Although the mechanisms for selegiline's beneficial action in the treatment of Parkinson's disease are not fully understood, the selective, irreversible inhibition of monoamine oxidase type B (MAO-B) is thought to be of primary importance. MAO-B is involved in the oxidative deamination of dopamine in the brain. Selegiline binds to MAO-B within the nigrostriatal pathways in the central nervous system, thus blocking microsomal metabolism of dopamine and enhancing the dopaminergic activity in the substantial nigra. Selegiline may also increase dopaminergic activity through mechanisms other than inhibition of MAO-B. At higher doses, selegiline can also inhibit monozmine oxidase type A (MAO-A), allowing it to be used for the treatment of depression.

  • Pharmacodynamics:

    Dopamine is an essential chemical that occurs in many parts of the body. It is the premature degradation of dopamine that results in the symptoms of Parkinson's disease. Monoamine oxidase (MAO) is an enzyme which accelerates the breakdown of dopamine. Selegiline can prolong the effects of dopamine in the brain by preventing its breakdown through seletively blocking MAO-B. It also may prevent the removal of dopamine between nerve endings and enhance release of dopamine from nerve cells.

  • Toxicity:

    LD50=63 mg/kg (rats, IV)

  • IUPAC: Benzeneethanamine, N, alpha-dimethyl-N-2-propynyl-, (R)-
  • ATC: N04BD01
  • PubChem: 26757
  • DrugBank: DB01037 (APRD00525)
  • Formula: C13-H17-N
  • Molecular Mass: 187.2843
  • Synonyms: (-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine, (-)-Deprenil, (-)-Selegiline, (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine, (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin, (R)-(-)-Selegiline, Anipryl, Benzeneethanamine, N,alpha-methyl-N-2-propynyl-, (alphaR)-, Carbex, Eldepryl, Emsam, Jumex, L-Deprenalin, l-Deprenyl, l-E 250, Selegilina, Selegilina [INN-Spanish], Selegiline, Selegilinum, Selegilinum [INN-Latin], Selgene, UNII-2K1V7GP655, Zalapar
  • SMILES: C[C@H](Cc1ccccc1)N(C)CC#C
  • AHFS Code: 92:00.00 28:92.00
  • InChl: 1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1
  • General Reference:

    1. Engberg G, Elebring T, Nissbrandt H: Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther. 1991 Nov;259(2):841-7. Pubmed
    2. Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinsonês disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. Pubmed# Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84. Pubmed
    3. Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. Pubmed
    4. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinsonês disease. Clin Pharmacokinet. 2002;41(4):261-309. Pubmed
    5. Culpepper L, Kovalick LJ: A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry. 2008;10(1):25-30. Pubmed
    6. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service